Novo’s prize asset shows potential in Alzheimer’s
A small study has shown an interesting effect from one of Novo Nordisk’s best selling diabetes medications – In the treatment of Alzheimer’s. The Chief Science Officer calls it “exciting”, while the Danish scientist behind the study refers to “a path that one could begin to go down”.
BY STEFAN SINGH KAILAY & LOUISE WENDT JENSEN
Diabetes, obesity, liver disease, and now Alzheimer’s disease as well. Novo Nordisk has seemingly discovered a particularly potent molecule in the active ingredient liraglutid.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo A/S completes billion dollar transaction
For abonnenter
Novo Nordisk paves the way for bigger pay packages
For abonnenter
